NCT05494762View on ClinicalTrials.gov

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

August 25, 2022

Primary Completion Date

February 24, 2025

Study Completion Date

February 24, 2025

Conditions
Solid Tumor
Interventions
DRUG

BGB-B167

Intravenous administration

DRUG

Tislelizumab

Intravenous administration

Trial Locations (8)

2148

Blacktown Cancer and Haematology Centre, Blacktown

3000

Peter Maccallum Cancer Centre, Melbourne

3004

The Alfred Hospital, Melbourne

3168

Monash Health, Clayton

5037

Icon Cancer Centre Kurralta Park, Kurralta Park

91010-3012

City of Hope National Medical Center, Duarte

06520-8028

Yale University, Yale Cancer Center, New Haven

37203-1619

Tennessee Oncology, Pllc Nashville, Nashville

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT05494762 - Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter